RxDoctor Payments Data

Xiao Zhou, MD

Internal Medicine · Rockville, MDNPI 1285605576

Payments from drug & device makers

$2,290in general payments, 2019–2025

Across 68 payments — averaging $33.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Novo Nordisk$178
  • Glaukos Corporation$142
  • Ivantis, Inc$121
  • Pfizer$55
  • Corcept Therapeutics$54
  • plus $54 from 2 others

What the payments were for

  • Food & beverage$2,290100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,290 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$126,031
Medicare patients
194
Services billed
1,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate127$82,619
EliquisApixaban98$78,533
LinzessLinaclotide120$70,966
TradjentaLinagliptin68$49,665
VemlidyTenofovir Alafenamide23$35,281
RybelsusSemaglutide29$32,137
JardianceEmpagliflozin31$31,586
ProcritEpoetin Alfa13$17,637
Tresiba Flextouch U-100Insulin Degludec31$15,770
Doxepin Hcl52$15,739
TrulicityDulaglutide11$11,381
Telmisartan194$11,320
VascepaIcosapent Ethyl27$8,617
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate33$5,859
Atorvastatin Calcium588$5,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$15$82,619127 claims
PfizerEliquis$55$78,53398 claims
GileadVemlidy$1,686$35,28123 claims
Novo NordiskRybelsus$178$32,13729 claims
Lilly USA, LLCTrulicity$40$11,38111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →